SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Sep 27, 2019

Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Sept. 27, 2019 · CIK: 0001533040 · Accession: 0001683168-19-003079

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-233584

Date

September 27, 2019

Author

Gerrit Dispersyn

Form

CORRESP

Company

Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)

Letter

Phio Pharmaceuticals Corp.

257 Simarano Drive, Suite 101 | Marlborough, MA 01752

September 27, 2019

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attn: Donald Field

Re: Phio Pharmaceuticals Corp.

Registration Statement on Form S-1 (File No. 333-233584)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. (the “Company”) hereby respectfully requests that the effective date of the above-referenced registration statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on October 1, 2019, or as soon thereafter as practicable.

Very truly yours,
PHIO PHARMACEUTICALS CORP.

Show Raw Text

CORRESP
1
filename1.htm

Phio Pharmaceuticals
Corp.

257 Simarano Drive, Suite 101 | Marlborough,
MA 01752

September 27, 2019

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 Attn:      Donald Field

 Re: Phio Pharmaceuticals Corp.

    Registration Statement on Form S-1 (File
                                         No. 333-233584)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Phio Pharmaceuticals Corp. (the “Company”) hereby respectfully requests that
the effective date of the above-referenced registration statement on Form S-1 filed by the Company (the “Registration
Statement”) be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on October 1, 2019,
or as soon thereafter as practicable.

    Very truly yours,

    PHIO PHARMACEUTICALS CORP.

    /s/ Gerrit Dispersyn

    Gerrit Dispersyn, Dr. Med. Sc.

    President and Chief Executive Officer

cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP

SecProbe.io